Activation of aerobic glycolysis in cancer cells is well known as the Warburg effect, although its relation to cellcycle progression remains unknown. In this study, human colon cancer cells were labeled with a cell-cycle phasedependent fluorescent marker Fucci to distinguish cells in G 1 -phase and those in S þ G 2 /M phases. Fucci-labeled cells served as splenic xenograft transplants in super-immunodeficient NOG mice and exhibited multiple metastases in the livers, frozen sections of which were analyzed by semiquantitative microscopic imaging mass spectrometry. Results showed that cells in G 1 -phase exhibited higher concentrations of ATP, NADH, and UDP-N-acetylglucosamine than those in S and G 2 -M phases, suggesting accelerated glycolysis in G 1 -phase cells in vivo. Quantitative determination of metabolites in cells synchronized in S, G 2 -M, and G 1 phases suggested that efflux of lactate was elevated significantly in G 1 -phase. By contrast, ATP production in G 2 -M was highly dependent on mitochondrial respiration, whereas cells in S-phase mostly exhibited an intermediary energy metabolism between G 1 and G 2 -M phases. Isogenic cells carrying a p53-null mutation appeared more active in glycolysis throughout the cell cycle than wild-type cells. Thus, as the cell cycle progressed from G 2 -M to G 1 phases, the dependency of energy production on glycolysis was increased while the mitochondrial energy production was reciprocally decreased.
Introduction
One of the most significant features of cancer cells is activation of glycolysis even under aerobic conditions. The feature, which has been termed Warburg Effect (1), is observed not only in cancer cells but also in most of proliferating cells (2) . An increase in lactate production was found in G 1 phase in HeLa cells (3) . Inhibition of glycolysis halted cell-cycle progression in G 1 phase in HeLa cells (4) . Enhanced production of lactate with upregulation of glycolytic enzymes was also observed at G 1 -S transition in proliferating thymocytes (5) . These studies indicate that activity of glycolysis is tightly coupled with cell-cycle progression (6, 7) .
On the other hand, previous works have shown that mitochondrial oxidative phosphorylation has key roles in cell-cycle progression (8) . Progression of G 1 phase in Jurkat cells was shown to be correlated with activation of respiration (9) . Unregulated oxidative phosphorylation induces delayed cell-cycle progression in G 1 phase (10) (11) (12) . Hyperactivation of mitochondrial functions is critical for entry into S-phase (13) . Thus, increasing evidence has suggested that oxidative phosphorylation and glycolysis seem to be coupled with each other and tightly regulated as a function of individual cellcycle phase during proliferation. However, little information has been available for quantitative data for metabolites in vivo or those for metabolic flux of specific metabolic systems involving glycolysis, tricarboxylic acid cycle (TCA) cycle, and high-energy nucleotides in cancer cells or tissues.
In the present study, to investigate coordination between energy metabolism and cell-cycle progression of cancer cells in vivo, we have used a human colorectal cancer cell line HCT116 to provide a liver metastasis model in superimmunodeficient NOD/SCID/IL-2Rg c null (NOG) mice (14) (15) (16) (17) (18) . To examine energy metabolism of individual cancer cells in metastatic tumors, we used HCT116 cells labeled with a cell-cycle phase-dependent fluorescent marker system Fucci (19) . With this system, newly developed matrixassisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) with high spatial resolution enabled us to reveal spatial distributions and local concentrations of various metabolites in the cancer cells in different cell-cycle phases in vivo (20) . Application of metabolomic analyses using capillary electrophoresis/electrospray ionization/mass spectrometry (CE/ESI/MS; refs. 21, 22 ) allows us to determine fluxes of multiple metabolic pathways during cell-cycle progression in vitro (20, 23, 24) . MALDI-IMS analyses of metastatic tumors have shown that the cancer cells in G 1 phase were more active in glycolysis than those in the other phases. Under synchronized conditions in vitro, extracellular secretion of lactate seemed to be accelerated in G 1 phase. In contrast, the cells in G 2 -M phase exhibited the highest fraction of mitochondrial oxidative phosphorylation, whereas those in S-phase mostly exhibited an intermediary energy metabolism between G 1 and G 2 -M phases, indicating the phase-specific characteristics of energy management of the cancer cells.
Materials and Methods

Cell culture
Human colorectal cancer cell line HCT116 and human embryonic kidney cell line 293T was obtained from the American Type Culture Collection and the Riken Cell Bank, respectively. HCT116 and 293T cells were grown in McCoy's 5A and Dulbecco's modified Eagle medium (DMEM; Gibco), respectively, supplemented with 10% heat-inactivated FBS (Sigma), 200 U/mL penicillin (Gibco), and 200 mg/mL streptomycin (Gibco). HCT116 p53-null cells were a generous gift from Dr. B. Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD), and the absence of p53 was confirmed by Western blot analysis of cell lysates (data not shown). Glucose-free McCoy's 5A medium (Gibco) was used with addition of 3 or 1 g/L of either unlabeled or 13 C 6 -labeled D-glucose.
Generation of Fucci-HCT116 cell lines
Viral suspensions for introduction of either mKO2-hCdt1 (30/120) or mAG-hGem(1/110) were prepared with 293T cells as described previously (19, 25, 26) . A mixture of the viral suspensions was used to cotransduce HCT116 cells. Cells emitting both red (excitation, 488 nm; emission, 578 nm) and green (excitation, 488 nm; emission, 519 nm) fluorescence were sorted into 96-well plates by a flow cytometer (FACSAria, BD Biosciences). Resulting clones displaying both red (excitation, 543 nm; emission, 560 nm) and green (excitation, 488 nm; emission, 505-550 nm) fluorescence with similar intensities were chosen by using a confocal microscope (LSM510, Carl Zeiss).
Flow cytometry
Nonsynchronizing exponentially growing Fucci-HCT116 cells were incubated with 6 mg/mL Hoechst 33342 (Sigma) at 37 C for 30 minutes. Fluorescence intensity of mKO2, mAG, and Hoechst (excitation, 355 nm; emission, 450-480 nm) was measured using a flow cytometer (FACSAria, BD Biosciences). Synchronized Fucci-HCT116 cells were washed with cold PBS, fixed with 70% ice-cold ethanol, and stained with PBS containing 0.5 mg/ mL of 4 0 ,6-diamino-2-phenylindole (DAPI) for 30 minutes. Fluorescence intensity of DAPI was measured using a flow cytometer (EpicsXL, Beckman Coulter).
MALDI-IMS analyses of liver metastases of human colon cancer xenografts in vivo
Superimmunodeficient NOG mice (18) were purchased from Central Institute for Experimental Animals. To generate a mouse model for liver metastasis, Fucci-HCT116 cells (1 Â 10 6 cells) were injected into spleen of male mice (25-27 g; 15-weeks-old; n ¼ 7). At 10 days after transplantation, liver lobules of the mice fasted for 17 hours were excised under sevoflurane anesthesia and snap-frozen with liquid nitrogen (17) . Cryosections (5 mm) of the liver samples were thaw-mounted on indium-tin oxide slides (8-12 ohm/sq; Sigma; ref. 27) . Protocols for the abovementioned experiments were approved by Institutional Committee of Animal Care and Ethics in School of Medicine, Keio University.
Mass spectrometry was conducted in the negative ionization mode by using an atmospheric pressure MALDI-QIT-TOF-MS equipped with a 355 nm Nd:YAG laser (Shimadzu). Fluorescent images of metastatic foci on tissue slices were acquired with a built-in fluorescence microscope and 2 fluorescence mirror units (U-MGFPHO for green fluorescence and U-MWIG3 for red fluorescence; Olympus). Matrix application (27) and acquisition of MALDI imaging data (27) with spatial interval of 20 mm and data processing (27, 28) were carried out as described previously. Measurement points with Fucci-green fluorescence were considered to be cells in S þ G 2 -M phases. Measurement points with Fucci-red fluorescence proximal to cells in S þ G 2 -M phases were chosen as cells in G 1 phase because such cells were assumed to be growing actively. To calculate relative concentrations, signal intensities of a metabolite in individual measurement points were normalized by an average value in liver parenchyma of each mouse (Supplementary Fig. S1 ). Averages of relative concentrations for a metabolite were compared between S þ G 2 -M phases and G 1 phase.
Cell synchronization and CE/ESI/MS analysis
Cells were synchronized with double thymidine block method. Cells (1.5 Â 10 6 cells per 10 cm dish for metabolomic analysis) were seeded at 24 hours before the first application of thymidine and cultured in the complete medium (containing 1 g/L or 3 g/L glucose) supplemented with 2 mmol/L thymidine for 15 hours, followed by 10-hour incubation with thymidine-free complete medium, and finally incubated for 14 hours with the medium supplemented with 2 mmol/L thymidine. Then, cells were released into the complete medium without thymidine and were collected at 3, 7, and 12 hours after release. Before collection, cells were labeled with 13 C 6 -D-glucose (Isotec) for 5 minutes by exchanging with a glucose-free complete medium supplemented with the labeled glucose at either 1 g/L or 3 g/L.
Cell numbers and protein amounts were determined with additional sets of dishes prepared with the same procedures as described above. Cellular proteins were precipitated by addition of one-tenth volume of 100% (w/v) trichloroacetic acid on ice for 30 minutes followed with an acetone wash. Protein concentrations were determined using the bicinchoninic acid (BCA) method according to the manufacturer's instructions (Micro BCA protein assay, Pierce).
Metabolites were extracted from cells with a solvent composed of methanol, distilled water, and chloroform [methanol:water:chloroform ¼ 1:0.5:1 (v/v/v)]. After centrifugation at 20,000 g at 4 C for 15 minutes, the supernatants were filtered through 5 kDa cut-off filter (Millipore). Metabolites including those that had at least one 13 C atom in the filtrate were analyzed by using an Agilent CE Capillary Electrophoresis System equipped with an Agilent 1100 series MSD mass spectrometer, as described previously (24) . Labeled metabolites containing at least one 13 C atom in a molecule were collectively indicated as 13 
Lactate efflux assay
Concentrations of extracellular lactate were measured using a lactate dehydrogenase-based kit (F-kit L-Lactate, Roche Diagnostics). Amounts of lactate accumulated in media (0.2 mL) were assayed at 1, 2.75, 5, 6.75, 9, and 12 hours after releasing. Rates of lactate efflux were determined by measuring lactate amounts in media after 30 minutes from exchanging with fresh media at time points of 2.75, 6.75, and 12 hours.
Assays for reduced and oxidized forms of glutathione (GSH and GSSG)
Cells were collected in a solution containing 5% metaphosphoric acid and 100 mmol/L diethylenetriamine pentaacetate (Sigma). After centrifugation at 20,000 Â g at 4 C for 10 minutes, the supernatant were filtered through 0.45 mm filter (Millipore) for assays. GSH and GSSG were detected with an HPLC-coulometric electrode array detector (Coularray Detector, model 540 with 8 channels; ESA Bioscience ref. 29) .
Assays for activities of glycolytic enzymes and Western blot analysis
Cells were collected by scraping and suspended in extraction buffer containing 50 mmol/L Tris-acetate, pH 7.8, 10 mmol/L dithiothreitol, 1 mmol/L EDTA-Na, pH 8.0, and a cocktail of protease inhibitors (Roche). After sonication for 4 separate periods of 30 seconds at 200 W on ice, the suspensions were centrifuged at 20,000 Â g for 10 minutes, and the supernatants were saved. Activities of phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and pyruvate kinase (PK) were determined by monitoring changes in absorbance at 340 nm as described previously (5, 30, 31) .
Cells were lysed with 8 mol/L urea containing 10 mmol/L Tris-HCl (pH 7.4), 1 mmol/L EDTA. Protein extract (50 mg) were resolved by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (GE Healthcare). Membranes were blocked with PBS-based blocking buffer (#927-40000; LI-COR, Lincoln) and probed with the following primary antibodies: Rabbit anti-PFKP (#AP8135b; Abgent), mouse anti-PFKFB3 (#H00005209-M08; Abnova), and mouse anti-Vinculin (#V9131; Sigma-Aldrich). Bound antibodies were detected with secondary antibodies [IR dye-conjugated goat anti-rabbit IgG (#926-32211; LI-COR) for PFKP, sheep anti-mouse IgG (#NA9310; GE Healthcare, UK) for PFKFB3, and infrared (IR) dye-conjugated goat anti-mouse IgG (#926-32210; LI-COR) for Vinculin]. Signals were visualized with Immobilon Western chemiluminescent HRP substrate (Millipore) for PFKP or directly imaged for PFKP and Vinculin with infrared/chemiluminescent dual imaging system (Odyssey FC; LI_COR).
Mitochondrial DNA copy number
Total DNA was isolated from cells by using a DNeasy DNA extraction kit (Qiagen) and conventional phenolchloroform extraction. The relative copy number of cytochrome b gene to RPL13A gene was determined by quantitative real-time PCR (7300 real-time PCR system, Applied Biosystems). Sequences of the primers were described previously (32) .
Determination of reactive oxygen species
Fucci-HCT116 cells cultured with 96-well plates were loaded with medium containing 5 mmol/L CellROX Deep Red reagent (Invitrogen) and incubated at 37 C for 1 hour. The near-infrared fluorescence of CellROX Deep Red (excitation, 640 nm; emission, 670 nm) was detected using a fluorescence plate reader (Synergy 4, Biotek).
Mitochondrial inner membrane potential
HCT116 cells were seeded at 1 Â 10 5 cells in a 35 mm dish with 12 mm glass base (Iwaki) and synchronized as described above. After release, cells were cultured with 17 nmol/L tetramethylrhodamine ethylester (TMRE, Invitrogen) and 6 mg/mL Hoechst 33342 for 20 minutes in the dark. Fluorescence of TRME (excitation, 568 nm; emission, 590-630 nm) and Hoechst 33342 (excitation, 325-350 nm; emission, 400-416 nm) was detected by using a laser scanning confocal microscope (Olympus, FV10i).
Extracellular acidification rate
HCT116 and HCT116 p53-null cells were seeded at 2 Â 10 4 cells per well in 24-well plates (Seahorse Bioscience), and synchronized with the double thymidine method. After releasing for 2.5, 6.5, and 11.5 hours, the cells were equilibrated with DMEM without bicarbonate (Seahorse Bioscience) in a non-CO 2 incubator at 37 C for 30 minutes. Extracellular acidification rate (ECAR) were recorded simultaneously by using a Seahorse Bioscience XF24 plate reader at 3, 7, and 12 hours after releasing, according to the manufacturer's instruction (8) .
Statistical analysis
Data were analyzed by using Statcel3 software package (OMS Publishing Inc.). ANOVA was used to evaluate differences in data among S, G 2 -M, and G 1 phases in vitro. Paired Student t test was used to examine differences in data between S þ G 2 -M and G 1 phases in vivo. Values are expressed as mean AE SEM. P < 0.05 was considered statistically significant.
Results
Fucci-HCT116 cells in metastatic foci with higher ATP levels in G 1 phase than in S and G 2 -M phases
To study how energy metabolism is coordinated with cellcycle progression in cancer cells, we used human colon cancer HCT116 cells and their stable transfectants, Fucci-HCT116 cells, which were generated by introduction of the Fucci system into the parental cells. Flow cytometry of growing Fucci-HCT116 cells for expression of the Fucci markers showed red-, yellow-, and green-emitting populations. DNA contents of the cells stained with Hoechst 33342 indicated that cells in G 1 phase were red; cells in S-phase were yellow or green; cells in G 2 -M phase were green (Fig. 1A) . The introduction of the Fucci markers did not change the populations in G 1 , S, and G 2 -M phases from those in parental HCT116 cells (data not shown). To observe changes in metabolism in cell-cycle progression in vivo, we used a NOG mouse model for liver metastasis of Fucci-HCT116 cells. With MALDI-IMS, relative concentrations of metabolites, all of which we have described as successful quantitation (27) , in tumor cells were determined. Measurement points corresponding to tumor cells with Fuccigreen fluorescence (S þ G 2 -M phases) and those with Fuccired fluorescence (G 1 phase) were assigned precisely using built-in fluorescence image capturing system (Fig. 1B) . It was notable that the percentages of cells in S þ G 2 -M phases in vivo were smaller than those under culture conditions (Fig.  1B, Supplementary Table S1 , and see the following sections), suggesting that proliferation of cells in the metastatic foci was less active than those under culture conditions. Ion density images from MALDI-IMS displayed in situ distributions of 10 metabolites involved in energy and redox metabolism (Fig. 1C) .
Relative concentrations, which were normalized by values of parenchyma in each mouse, of ATP, UTP, NADH, UDP-N-acetylglucosamine (UDP-GlcNAc), and GSSG in cells in G 1 phase were found to be significantly greater than those in S þ G 2 -M phases in the foci (Fig. 1D and Supplementary  Fig. S1 ). On the other hand, relative concentrations of ADP, AMP, UDP, UMP, and GSH did not differ significantly between S þ G 2 -M and G 1 phases (Fig. 1D) . The results that the concentrations of nucleotide triphosphates and NADH were higher in G 1 phase cells than in S þ G 2 -M phase cells suggested that the cells exhibited cell-cycle phasedependent energy metabolism, possibly executing glycolysis more actively in G 1 phase than in the other phases.
Synchronization of Fucci-HCT116 cells in G 1 , S, and G 2 -M phases
As Fucci-HCT116 cells in S and G 2 -M phases both emitted green fluorescence, they could not be distinguished from each other by the fluorescence. To understand cellcycle-dependent changes in energy metabolism clearly, we used synchronized cells prepared in vitro with the double thymidine block method ( Fig. 2A-C) . At 3, 7, and 12 hours after release from the thymidine treatment, cells were harvested and DNA contents of the cells were analyzed by flow cytometry. The results indicated that the cells collected at 3 hours were almost in S-phase (75%); those at 7 hours were in G 2 -M phase (85%); and those at 12 hours were in G 1 phase (88%; Fig. 2B ). Fluorescence microscopy of the synchronized Fucci-HCT116 cells showed that more than 70% of cells emitted green or yellow fluorescence at 3 and 7 hours after the release; and 89% of the cells emitted red fluorescence at 12 hours after the release (Fig. 2C) . Thus, the detected fluorescence introduced by Fucci system was consistent with the classical methodology.
For general characterization of Fucci-HCT116 cells in different cell-cycle phases, we examined cell numbers, cell volumes, and protein amounts of the synchronized populations, which were derived from the same numbers of cells inoculated before thymidine treatment. As shown, the cell numbers unchanged from S to G 2 -M phase, and then increased twice in G 1 phase (Fig. 2D) . The volumes of individual cells reached the maximum in G 2 -M phase and showed a dramatic decrease in G 1 phase (Fig. 2E and F) . The total protein amounts of collected cells in different phases tended to increase gradually (Fig. 2G) . The protein amounts per cell decreased in G 1 phase by 36% from that in G 2 -M phase (Fig. 2H) , whereas the protein amounts per cell volume in G 1 phase increased by 58% from those in G 2 -M phase (Fig. 2I) . These observations through cell-cycle progression may help to understand changes in the energy metabolism in the following sections.
Higher ATP levels in G 1 phase than in S and G 2 -M phases of HCT116 cells in vitro
To know whether in vitro cells exhibited cell-cycle phasedependent metabolic changes similar to those seen in vivo, we used synchronized cells in S, G 2 -M, and G 1 phases in vitro and determined cellular concentrations of the same set Ã , P < 0.05; ÃÃ , P < 0.01. See also Supplementary Table S1 for percentages of green-and red-fluorescent nuclei in foci of 7 mice, Supplementary Table S2 for numbers of measurement points from the foci, and Supplementary Fig. S1 for frequency distributions of relative MALDI-IMS signal intensities of measurement points to liver parenchyma in mouse number 3. of the metabolites as examined in vivo except for UDPGlcNAc. Under conditions in culture, ATP concentration in G 1 phase was significantly higher than the other phases, whereas calculated values for energy charge did not change among the 3 phases (Fig. 3A) . GSH and GSSG concentrations were both greater in G 1 phase than in the other phases significantly (Fig. 3B) .
Next, to obtain comprehensive information on changes in energy metabolism in cell-cycle progression, we measured various metabolites in glycolysis, TCA cycle, and PPP in S, G 2 -M, and G 1 phases by using CE/ESI/MS. The samples were prepared from synchronized cells which were derived from same numbers of inoculated cells. Molar amounts were used for comparison of the data among the cell-cycle phases. For analyses of metabolic flux, cells were labeled with medium containing 13 C 6 -labeled glucose for 5 minutes before extraction. Amounts of lactate, pyruvate, and total amounts of glycolytic metabolites did not change in the cellcycle progression (Fig. 4A-C) . It should be noted that cellular amounts of lactate were predominant among the metabolites of the 3 pathways through the cell-cycle phases. The cellular amounts of the metabolites in each of the 3 pathways were almost unchanged in the cell-cycle progress (Fig. 4C) . Amounts of 13 C-labeled metabolites (at least one carbon atom was labeled) showed that the metabolites in glycolytic pathway were labeled more quickly than those in TCA cycle and in PPP (data not shown) in the cell-cycle progression ( Fig. 4D and E) .
As HCT116 cells whose data described above carry wildtype p53, a key regulator of glycolysis, we also collected data from isogenic HCT116 cells with p53-null mutation and from wild-type cells cultured at a euglycemic level (1 g/L). Fig. S3-S5 ).
Glycolysis is accelerated in G 1 phase to greater extents than the other phases Because lactate was the predominant metabolite which is released from cells as a result of glycolysis, we next examined amounts of extracellular lactate in the progress of cell cycle. When accumulation of extracellular lactate after wash-out of thymidine was examined, wild-type cells under 3 g/L glucose showed gradual increases in lactate levels with a small decrease in slope at G 2 -M phase (Fig. 5A , dots with solid line). Measurements of release rates of lactate by replacing with fresh media indicated that the observed rate in G 1 phase was higher than S and G 2 -M phases with statistical significances (Fig. 5B, dots with solid line) . These results suggest that glycolysis is markedly accelerated in G 1 phase to greater extents than the other phases.
Extracellular lactate was being accumulated in wild-type cells at a euglycemic level with a similar manner, except for a marked halt in G 2 -M phase, as seen under 3 g/L glucose condition (Fig. 5A, gray squares with gray line) . On the other hand, extracellular lactate in p53-null cells at 3 g/L glucose was being accumulated with almost linear pattern throughout the cell-cycle progression (Fig. 5A , triangles with dashed line). These observations were consistent with releasing rates of lactate ( Fig. 5B and Supplementary Fig. S6 ). Furthermore, when the releasing rates, which were normalized by cell numbers, were compared among the three sets of the data, p53-null mutation might activate glycolysis (Fig. 5C) .
Although intracellular lactate level was not significantly changed between genotypes or culture conditions during cell-cycle progression (Fig. 4A) , ECAR, marker for lactate production rate, was significantly increased in G 1 phase in HCT116 WT cells cultured with both 1 g/L and 3 g/L of glucose and HCT116 p53-null cells with 1 g/L glucose ( Fig. 5D and E) . We have also checked the expression of several monocarboxylate transporters (MCT) as extracellular lactate level depends on both import and export rate of lactate. mRNA expression levels of MCT1 and MCT4 did not change significantly throughout cell-cycle progression, suggesting that lactate efflux might not depend on expression level of lactate transporters ( Supplementary  Fig. S7 ).
Glycolytic enzyme activities may explain in part changes in glycolytic rates in cell-cycle progression
We measured activities of a certain set of glycolytic enzymes to investigate possible causes of the changes in glycolytic activities throughout cell-cycle phases. Soluble proteins were extracted from cells in S, G 2 -M, and G 1 phases, which were derived from the same number of cells, and enzymatic activities of PFK, GAPDH, and PK were examined. The activities of the three enzymes in S, G 2 -M, and G 1 phases gave similar patterns to one another; for all of the three enzymes, the activities in S and G 1 phases were similar to each other and higher than those in G 2 -M phase (Fig. 6A-C) . These results may explain in part changes in Figure 5 . Glycolysis is accelerated in G1 phase to greater extents than in other phases. A, amounts of lactate accumulated in media (0.2 mL) were assayed at 1, 2.75, 5, 6.75, 9, and 12 hours after releasing. Note that acuumulation rate was temporary decreased at G 2 -M phase in HCT116 WT cells. B, rates of lactate efflux were examined by measuring lactate amounts in media after 30 minutes from exchanging with fresh media at time points of 2.75, 6.75, and 12 hours. Statistical significance was examined for differences in data between 2 successive time points. C, rates of lactate efflux were normalized by cell numbers. Statistical significance was examined for differences in data of either wild-type cells (1 g/L glucose) or p53-null cells (3 g/L glucose) from wild-type cells (3 g/L glucose) at individual time points. n ¼ 3, mean values AE SEM. Ã , P < 0.05; ÃÃ , P < 0.01. D and E, ECARs were real-time measured using Seahorse XF24 Analyzer in HCT116 WT and HCT116 p53-null cells in indicated cell-cycle phases (S, G 2 -M and G 1 ) as described in Materials and Methods section. n ¼ 6, mean values AE SEM. Ã , P < 0.05; ÃÃ , P < 0.01.
glycolytic rates (Fig. 5B , solid line) and ECAR (Fig. 5D , wild-type cells in 3 g/L glucose) in cell-cycle progression. We further examined protein levels of PFKP, a subunit of PFK, and PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) in the cell-cycle progression of the wild-type cells and p53-null cells in both high (3 g/L) and low (1 g/L) glucose concentrations. Western blot analyses indicated that the levels of the proteins in the 2 types of cells did not significantly alter in the cell-cycle progression under both glucose concentrations (Fig. 6D) . The enzyme amounts did not necessarily account for the changes in glycolytic activity in the cell-cycle progression.
Mitochondrial oxidative phosphorylation is activated in G 2 -M phase
We subsequently examined how mitochondrial oxidative phosphorylation activity changed in the cell-cycle progression. Measurements of oligomycin-sensitive ATP production showed that percentages of mitochondrial production of ATP were the highest (41%) in G 2 -M phase and the lowest (9%) in G 1 phase (Fig. 7A) without apparent changing in mitochondrial DNA copy number over genomic DNA (Fig. 7B) . Thus, dependence of ATP synthesis on mitochondria was higher in G 2 -M phase than in G 1 phase. The levels of cellular ROS, a by-product from the electron transfer, were the highest in G 2 -M phase among the cell-cycle phases (Fig. 7C) , suggesting the most active electron transfer activity in the phase. Inner mitochondrial membrane potential in G 1 phase, however, was kept being 1.5-fold higher than in S and G 2 -M phases, implying that the potential was not so efficiently consumed to produce ATP in G 1 phase as in S and G 2 -M phases (Fig. 7D) .
Discussion
In the present study, we deepened the understanding of energy metabolism of cancer cells. This was carried out by measuring metabolites of synchronized cells in vitro in different cell-cycle phases using mass spectrometry. We showed that glycolysis was dominant in the energy metabolism throughout the cell-cycle progression with an enhancement in G 1 phase, whereas mitochondrial oxidative phosphorylation was reciprocally activated in S and further in G 2 -M phases. Consequently, these results together with the current observations in vivo provided for the first time substantial evidence for the cell-cycle-dependent patterns in energy metabolism of cancer cells in vitro and in vivo.
This study added a new viewpoint of cell-cycle phases to the energy metabolism including the Warburg effect. Previous studies focusing on a segment in energy-acquiring metabolisms or specific metabolites have shown cyclic changes in oxygen consumption (33) , concentrations of glycolytic intermediates (34) , ATP (35) , and lactate (3) in proliferating cells. Since these studies have not examined the whole pathways of energy metabolism in different cell-cycle phases, they did not depict an overall picture of the energy metabolism throughout cell proliferation processes. In contrast, our study dissected metabolic systems for energy management into glycolysis, oxidative phosphorylation, and PPP and used in vitro cancer cells synchronized in S, G 2 -M, and G 1 phases.
Several lines of evidence indicate cell-cycle phase-dependent changes in energy metabolism in culture where sufficient amounts of glucose and oxygen are available. First, the energy production in G 1 phase highly depends on glycolysis with only a small fraction of mitochondrial respiration. Data of the metabolite measurements, especially extracellular lactate, suggested that the glycolytic activity was the most active in G 1 phase. Inversely, the mitochondrial contribution to ATP production was also minimal in G 1 phase. Thus, Warburg effect was seen most evidently in the G 1 -phase cancer cells. Second, the G 2 -M phase exhibited the highest dependence of energy production on mitochondrial respiration. The fraction of mitochondrial ATP production were the highest values in G 2 -M phase together with the greatest levels of ROS production presumably because of the active electron-transferring activities. Third, the energy metabolism in S-phase mostly exhibited an intermediary between G 1 and G 2 -M phases. Thus, as the cell cycle progressed from G 2 -M to G 1 phases, the dependence of energy production on glycolysis in the cancer cells was drastically increased, whereas mitochondrial contribution was reciprocally decreased. As discussed later, since energization in G 1 phase is a requisite for passing through the metabolic checkpoint (10, 36, 37) , the enhancement of glycolysis in G 1 phase may energize the cells and avoid G 1 arrest.
The combination of the Fucci system, the mouse model for metastasis, and the MALDI-IMS in this study cast new light on in vivo studies on energy metabolism of solid cancer. In fact, the significant increase in concentrations of ATP and UTP in G 1 phase was greater than in S and G 2 -M phases in vivo. As UDP-GlcNAc levels are elevated in parallel with glucose use (38) , the current observation showing the higher level of UDP-GlcNAc in G 1 phase in vivo suggests a possible accelerated glucose uptake in the phase. When the concentrations of metabolites were compared between in vitro and in vivo, there were some discrepancy, i.e., cellular amounts of GSH were greater in G 1 than in G 2 -M phase in vitro, whereas they did not statistically differ in vivo. The discrepancy between in vitro and in vivo might result from different conditions such as supplies of oxygen and nutrients. In The enhancement of glycolysis in G 1 phase is a distinct feature that may be exploited for control of cell-cycle progression in cancer cells. Between G 1 and S phases, there is a metabolic checkpoint that determines whether cells undergo G 1 arrest or proliferate (36, 37) . AMP-activated protein kinase (AMPK) serves as a sensor for low energy, and its activation inhibits cell growth through mechanisms involving inhibition of mTOR (39) . Accordingly, activators of AMPK and inhibitors of mTOR have been shown to account for candidates for chemotherapeutics for tumor growth suppression (37, 40) . On the contrary, using the nature of G 1 cells that execute enhanced use of glucose could be another pharmacologic modality. Management of energy status by upregulation of glycolysis in G 1 phase possibly increases cell populations in S and G 2 -M phases. As we showed, the cell populations in S and G 2 -M phases were only less than 10% in vivo (Supplementary Table S1 ), whereas percentages of the same population become much greater in culture (Fig. 2) . These results together with the observation that hypoxia induces G 1 arrest in various cancer cells (41, 42) suggest that a considerable population of cells in the metastatic foci in vivo may be under G 1 arrest presumably because of insufficient nutritional states and/or relatively low O 2 concentrations (17) . Considering that most of anticancer chemotherapeutic agents target cells in S or G 2 -M phases, rendering tumor cells under G 1 phase highly active in glycolysis and proliferative may cause increasing sensitivity to drugs by passing these cells through the metabolic checkpoint to undergo S and G 2 -M phases.
Under euglycemic levels of glucose, HCT116 cells also exhibited the above-mentioned metabolic features which were observed under the hyperphysiologic levels (3 g/L glucose). This fact may have a biologic significance that such enhancement of glycolysis could occur in cancer cells under euglycemic environment in vivo. Since it has been known that p53 inactivation contributes to glucose consumption by modulating activities of metabolic pathways (43, 44) , a question may arise whether such metabolic features could be affected by p53-null. As expected, our results using its isogenic derivative lacking p53 showed that p53 null mutation raised lactate production by 1.5-fold throughout the cellcycle progression (Fig. 5B) . Accordingly, it was likely that a reduction of glycolysis dependence in G 2 -M phase of cells lacking p53 is smaller than wild-type cells. Thus, the current finding that transient increase in dependence on oxidative phosphorylation in G 2 -M phase and enhancement of glycolysis in G 1 phase may be more obvious with cells carrying wild-type p53 than those lacking p53. 
